St.Gallen会议乳腺癌新辅助治疗回顾

doi:10.6040/j.issn.1671-7554.0.2017.899

摘要/Abstract

摘要： 新辅助治疗作为局部晚期乳腺癌的治疗方式,可使不可手术的乳腺癌转为可手术,为不可保乳的患者,最终保留了乳房。现今,一些新的证据又赋予了新辅助治疗新的使命,包括筛选敏感药物,使患者病情达到病理完全缓解,从而生存获益;另外,使腋窝病理缓解的患者避免腋窝清扫。本文综述了St.Gallen乳腺癌会议上新辅助治疗的最新进展。

关键词: 乳腺癌, 新辅助治疗, 病理完全缓解, 保乳手术, 腋窝清扫, 化疗, 内分泌

Abstract: Neoadjuvant therapy is the standard treatment for local advanced breast cancer. Some inoperable breast cancer can be operated and some patients who should not undergo breast conservative surgery can keep their breast after neoadjuvant therapy. Nowadays, based on new evidences, there are new missons in neoadjuvant therapy, such as screening out sensitive drugs for the patients who may acquire pathological complete reaction in order to gain survival benefits and 山东大学学报 (医学版)56卷1期 -石爱平,等.St.Gallen会议乳腺癌新辅助治疗回顾 \=-avoiding axillary dissection for some patients who are clinically nodes positive at diagnosis and downstage. The new progress of neoadjuvant therapy at St. Gallen conference will be reviewed in the paper.

Key words: Breast cancer, Neoadjuvant therapy, Pathologic complete response, Breast-conserving surgery, Axillary dissection, Chemotherapy, Endocrinotherapy

中图分类号:

R605

石爱平,徐格格,解新鹏. St.Gallen会议乳腺癌新辅助治疗回顾[J]. 山东大学学报 (医学版), 2018, 56(1): 6-11.

SHI Aiping, XU Gege, XIE Xinpeng. Review of neoadjuvant therapy for breast cancer at the St.Gallen conference[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 6-11.

参考文献

[1] Habel LA, Dignam JJ, Land SR, et al. Mammographic density and breast cancer after ductal carcinoma in situ[J]. J Natl Cancer Inst, 2004, 96(19): 1467-1472.
[2] Golshan M, Cirrincione CT, Sikov WM, et al. Alliance for Clinical Trials in Oncology. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603(Alliance)[J]. Ann Surg, 2015, 262(3): 434-439.
[3] Landercasper J, Bennie B, Parsons BM, et al. Fewer reoperations after lumpectomy for breast cancer with neoadjuvant rather than adjuvant chemotherapy: a report from the national cancer database[J]. Ann Surg Oncol, 2017, 24(6): 1507-1515.
[4] Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer[J].Ann Surg Oncol, 2012, 19(10): 3177-3184.
[5] Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer[J]. Br J Surg, 2007, 94(10): 1189-1200.
[6] Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Natl Cancer Inst Monogr, 2001(30): 96-102. doi: 10.1093 /oxfordjournals.jncimonographs.a003469.
[7] El-Didi MH, Moneer MM, Khaled HM, et al. Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management[J]. Surg Today, 2000, 30(3): 249-254.
[8] Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience[J]. J Clin Oncol, 2004, 22(12): 2303-2312.
[9] Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2015, 22(4): 1118-1127.
[10] Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype[J]. J Clin Oncol, 2011, 29(6): 660-666.
[11] Mukhtar RA, Yau C, Rosen M, et al. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL(CALGB 150007/150012; ACRIN 6657)[J]. Ann Surg Oncol, 2013, 20(12): 3823-3830.
[12] FelicianoY, Mamtani A, Morrow M, et al. Do calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised?[J]. Ann Surg Oncol, 2017, 24(6):1492-1498.
[13] Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071(Alliance)clinical trial[J]. JAMA, 2013, 310(14): 1455-1461.
[14] Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy(SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
[15] Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264.
[16] Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study[J]. Ann Surg Oncol, 2016, 23(11): 3467-3474.
[17] Krag DN, Julian TB, Harlow SP, et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial[J]. Ann Surg Oncol, 2004, 11(3 Suppl): 208-210.
[18] Chang JM, Kosiorek HE, Wasif N, et al. The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review[J]. Am J Surg, 2017, 214(6):1096-1101.
[19] Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection[J]. J Clin Oncol, 2016, 34(10): 1072-1078.
[20] Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281.
[21] Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer(NSABP B-40[NRG Oncology] ): secondary outcomes of a phase 3, randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1037-1048.
[22] Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study(GBG 44)[J]. Ann Oncol, 2013, 24(12): 2978-2984.
[23] Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21.
[24] Isakoff SJ, Mayer EL, He L, et al.TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer[J]. J Clin Oncol, 2015, 33(17): 1902-1909.
[25] Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the geparsixto randomized clinical trial[J]. JAMA Oncol, 2017, 3(10):1378-1385.
[26] Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer(GeparSepto-GBG 69): a randomised, phase 3 trial[J]. Lancet Oncol, 2016, 17(3): 345-356.
[27] Schettini F,Giuliano M,De Placido S,et al. Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives[J]. Cancer Treat Rev, 2016, 50: 129-141. doi: 10.1016/j.ctrv.2016.09.004.
[28] Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups[J]. J Clin Oncol, 2011, 29(25): 3351-3357.
[29] Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer(NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[30] Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006[J]. J Clin Oncol, 2013, 31(14): 1726-1731.
[31] Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32.
[32] Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study(TRYPHAENA)[J]. Ann Oncol, 2013, 24(9): 2278-2284.
[33] Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2012, 379(9816): 633-640.
[34] Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer(NSABP protocol B-41): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(12): 1183-1192.
[35] Harbeck N, Gluz O, Christgen M, et al. De-escalation strategies in human epidermal growth factor receptor 2(HER2)-positive early breast cancer(BC): final analysis of the west german study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy(ET)versus trastuzumab plus ET[J]. J Clin Oncol, 2017, 35(26): 3046-3054
[36] Ellis MJ. Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer[J]. Breast, 2017, 34(Suppl 1): 104-107.
[37] Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer[J]. Cancer, 2007, 110(2): 244-254.
[38] Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics[J]. J Natl Cancer Inst, 2008, 100(19): 1380-1388.
[39] Yeo B, Dowsett M. Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints[J]. Breast, 2015, 24(Suppl 2): 78-83.
[40] Kolberg HC, Aktas B, Liedtke C. Clinical utility of neoadjuvant endocrine therapy for hormone receptor positive breast cancer[J]. Rev Recent Clin Trials, 2017, 12(2): 67-72.
[41] Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial[J]. J Clin Oncol, 2001, 19(18): 3808-3816.
[42] Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031[J]. J Clin Oncol, 2011, 29(17): 2342-2349.
[43] Ellis MJ, Suman VJ, Hoog J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial(Alliance)[J]. J Clin Oncol, 2017, 35(10): 1061-1069.
[44] Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22): 2147-2159.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed